10,610 Shares in scPharmaceuticals Inc. (NASDAQ:SCPH) Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. acquired a new position in shares of scPharmaceuticals Inc. (NASDAQ:SCPH) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 10,610 shares of the company’s stock, valued at approximately $38,000.

A number of other institutional investors have also recently added to or reduced their stakes in SCPH. BNP Paribas Financial Markets lifted its holdings in shares of scPharmaceuticals by 116.9% in the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after purchasing an additional 3,101 shares in the last quarter. Captrust Financial Advisors lifted its holdings in shares of scPharmaceuticals by 32.2% in the third quarter. Captrust Financial Advisors now owns 18,539 shares of the company’s stock valued at $85,000 after purchasing an additional 4,513 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in shares of scPharmaceuticals by 135.0% in the third quarter. MetLife Investment Management LLC now owns 16,974 shares of the company’s stock valued at $77,000 after purchasing an additional 9,752 shares in the last quarter. Virtu Financial LLC purchased a new stake in shares of scPharmaceuticals in the third quarter valued at about $46,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of scPharmaceuticals in the third quarter valued at about $57,000. Hedge funds and other institutional investors own 89.52% of the company’s stock.

scPharmaceuticals Stock Performance

NASDAQ:SCPH opened at $3.35 on Wednesday. The firm has a 50 day simple moving average of $3.41 and a 200-day simple moving average of $4.15. The company has a debt-to-equity ratio of 1.66, a current ratio of 8.08 and a quick ratio of 6.89. The firm has a market cap of $167.63 million, a PE ratio of -1.76 and a beta of 0.11. scPharmaceuticals Inc. has a 1-year low of $3.08 and a 1-year high of $6.54.

Analyst Ratings Changes

Several analysts have issued reports on SCPH shares. Craig Hallum reduced their price target on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of scPharmaceuticals in a research report on Thursday, November 14th.

scPharmaceuticals Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.